Prognostic Utility of Combining VI-RADS Scores and CYFRA 21-1 Levels in Bladder Cancer: A Retrospective Single-Center Study
Current Oncology · 2025
DOI: 10.3390/curroncol32080415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Shunsuke Ikuma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. Hauptthemen laut MEDLINE: Keratin-19, Urinary Bladder Neoplasms, Antigens, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The Vesical Imaging Reporting and Data System (VI-RADS) is used to detect muscle-invasive bladder cancer, with emerging prognostic implications. Integrating imaging parameters with molecular biomarkers may improve risk stratification in bladder cancer. This study evaluated whether combining VI-RADS scores with serum cytokeratin fragment 19 (CYFRA 21-1) levels—a clinically relevant biomarker for bladder cancer—could improve overall survival (OS) prediction. We retrospectively analyzed 134 patients who underwent transurethral resection of bladder tumors, magnetic resonance imaging, and postoperative serum CYFRA 21-1 measurements. In total, 15 cancer-specific deaths were observed during follow-up. Receiver operating characteristic curve analysis identified optimal prognostic cut-off values: VI-RADS score ≥ 4 and CYFRA 21-1 level ≥ 1.8 ng/mL. The 1-, 2-, and 3-year OS in patients with both high VI-RADS scores and CYFRA 21-1 levels were 42.9%, 16.7%, and 8.3%, respectively, significantly lower than those in other groups (p < 0.001, 0.002, and 0.003, respectively). Multivariate Cox proportional hazards analysis demonstrated that such patients had the poorest OS (hazard ratio: 7.51; p = 0.002). This suggests that combining VI-RADS and CYFRA 21-1 improves prognostic accuracy in bladder cancer, demonstrating potential clinical utility by informing individualized treatment strategies; however, limitations include the retrospective study design and absence of external validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
ORCID-Profile: Shunsuke Ikuma, Hayato Takeda, Yuki Endo, Go Kimura, Yukihiro Kondo
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Ikuma, S., Akatsuka, J., Kaneko, G., Takeda, H., Endo, Y., Kimura, G., & Kondo, Y. (2025). Prognostic Utility of Combining VI-RADS Scores and CYFRA 21-1 Levels in Bladder Cancer: A Retrospective Single-Center Study. Current Oncology. https://doi.org/10.3390/curroncol32080415
Vancouver
Ikuma S, Akatsuka J, Kaneko G, Takeda H, Endo Y, Kimura G, et al. Prognostic Utility of Combining VI-RADS Scores and CYFRA 21-1 Levels in Bladder Cancer: A Retrospective Single-Center Study. Current Oncology. 2025. doi:10.3390/curroncol32080415
BibTeX
@article{Ikuma2025,
author = {Ikuma, Shunsuke and Akatsuka, Jun and Kaneko, Godai and Takeda, Hayato and Endo, Yuki and Kimura, Go and Kondo, Yukihiro},
title = {Prognostic Utility of Combining VI-RADS Scores and CYFRA 21-1 Levels in Bladder Cancer: A Retrospective Single-Center Study},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32080415}
}
EUVIMED